Blueprint Medicines Co. (NASDAQ:BPMC) Insider Ariel Hurley Sells 3,203 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 3,203 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total value of $296,661.86. Following the sale, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. The trade was a 14.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ariel Hurley also recently made the following trade(s):

• On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The shares were sold at an average price of $100.00, for a total value of $225,000.00.
• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The shares were sold at an average price of $93.26, for a total value of $169,639.94.

Blueprint Medicines Stock Down 0.4 %

NASDAQ:BPMC traded down $0.37 during mid-day trading on Tuesday, reaching $89.38. The company’s stock had a trading volume of 1,385,852 shares, compared to its average volume of 1,018,106. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90. The stock has a fifty day moving average of $99.52 and a 200-day moving average of $94.37. The firm has a market capitalization of $5.71 billion, a PE ratio of -82.76 and a beta of 0.62.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Equities research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Institutional Trading of Blueprint Medicines

A number of hedge funds have recently bought and sold shares of BPMC. Empirical Asset Management LLC purchased a new position in shares of Blueprint Medicines in the 4th quarter valued at $2,348,000. Stephens Inc. AR bought a new stake in Blueprint Medicines during the fourth quarter valued at about $321,000. Massachusetts Financial Services Co. MA grew its stake in Blueprint Medicines by 48.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 252,236 shares of the biotechnology company’s stock valued at $23,332,000 after purchasing an additional 82,693 shares during the last quarter. Entropy Technologies LP bought a new position in Blueprint Medicines in the third quarter worth about $999,000. Finally, KBC Group NV lifted its position in shares of Blueprint Medicines by 63.9% during the fourth quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 1,023 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have commented on BPMC shares. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Friday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price target on shares of Blueprint Medicines in a report on Thursday, February 13th. Wedbush reissued an “outperform” rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research report on Friday. Piper Sandler boosted their target price on Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research note on Friday, February 14th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $123.83.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.